Story perspectives

FDA Advisers Vote on Approving Galleri Multi-Cancer Test

By Drooid · Sep 23, 2026, 5:47 PM UTC · How we work

Summary

Story summary

FDA advisers will vote on approving Grail’s Galleri multi-cancer blood test.
FDA staff reviewers reported no major safety or accuracy issues in the briefing.
Galleri screens for over 50 cancers and costs $949 per test.
The test earned $136.8 million in U.S. revenue in 2025.
Shares rose about 35% after the briefing, trading above $107 per share.

1 of 1

Story summary

FDA advisers will vote on approving Grail’s Galleri multi-cancer blood test.
FDA staff reviewers reported no major safety or accuracy issues in the briefing.
Galleri screens for over 50 cancers and costs $949 per test.
The test earned $136.8 million in U.S. revenue in 2025.
Shares rose about 35% after the briefing, trading above $107 per share.